Tempus reported preliminary fourth-quarter revenue of about $367 million, up roughly 83% year over year, and beat Street estimates. The Chicago-based company attributed the gain primarily to testing volume growth: diagnostics revenue nearly doubled to an expected $266 million, driven by oncology and hereditary disease testing volume increases. Tempus also flagged growth in data and applications revenue and revealed over $1.1 billion in total contract value from more than 70 customers. Management will present at JPM; the results highlight diagnostics and data licensing as core revenue engines for clinical AI-enabled companies.